leadf
logo-loader
viewCytoDyn Inc.
(
OTCQB:CYDY
)

Full interview: CytoDyn to present HIV prevention data at HIV research meeting in Boston

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive that an abstract on the potential of its drug candidate leronlimab for the prevention of HIV has been accepted for presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Pourhassan says acceptance of the abstract as late-breaking describes leronlimab’s significant assistance in HIV prevention.

Quick facts: CytoDyn Inc.

Follow
OTCQB:CYDY

Price: 2.3 USD

Market Cap: $1.45 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn treats first patient with flagship drug in its Phase 3 coronavirus...

CytoDyn Inc CEO Nader Pourhassan tells Proactive it has treated the first patient with its flagship drug candidate leronlimab (Vyrologix or PRO 140) in a pivotal Phase 3 coronavirus trial in Brazil for patients with severe symptoms. Pourhassan says an interim analysis will be conducted 28...

1 week, 5 days ago

2 min read